See more : GoviEx Uranium Inc. (0UYS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Relay Therapeutics, Inc. (RLAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Relay Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ZhongWang Fabric Co., Ltd. (605003.SS) Income Statement Analysis – Financial Results
- Certara, Inc. (CERT) Income Statement Analysis – Financial Results
- Forest Road Acquisition Corp. II (FRXB) Income Statement Analysis – Financial Results
- Mountain Boy Minerals Ltd. (MBYMF) Income Statement Analysis – Financial Results
- Shenzhen Zhongheng Huafa Co., Ltd. (200020.SZ) Income Statement Analysis – Financial Results
Relay Therapeutics, Inc. (RLAY)
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 25.55M | 1.38M | 3.03M | 82.65M | 0.00 | 0.00 |
| Cost of Revenue | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| Gross Profit | 20.28M | -2.75M | -896.00K | 79.11M | -2.85M | -2.15M |
| Gross Profit Ratio | 79.37% | -199.06% | -29.58% | 95.71% | 0.00% | 0.00% |
| Research & Development | 330.02M | 246.36M | 172.65M | 99.86M | 70.31M | 41.03M |
| General & Administrative | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Other Expenses | 0.00 | -20.00K | -4.00K | -16.00K | -58.00K | -9.00K |
| Operating Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Cost & Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Interest Income | 31.05M | 8.79M | 830.00K | 3.40M | 8.80M | 1.11M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| EBITDA | -374.15M | -306.82M | -222.18M | -52.25M | -81.20M | -47.74M |
| EBITDA Ratio | -1,464.62% | -23,361.98% | -2,948.70% | -63.21% | 0.00% | 0.00% |
| Operating Income | -373.00M | -299.28M | -364.70M | -55.80M | -84.05M | -49.89M |
| Operating Income Ratio | -1,460.11% | -21,670.89% | -12,040.21% | -67.51% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.03M | 8.77M | 826.00K | 3.38M | 8.74M | 1.10M |
| Income Before Tax | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M | -48.79M |
| Income Before Tax Ratio | -1,338.66% | -21,036.13% | -12,012.94% | -63.41% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -36.25M | 132.94M | -3.40M | -8.80M | 1.10M |
| Net Income | -341.97M | -254.26M | -496.81M | -49.01M | -66.50M | -48.79M |
| Net Income Ratio | -1,338.66% | -18,411.22% | -16,401.72% | -59.30% | 0.00% | 0.00% |
| EPS | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EPS Diluted | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| Weighted Avg Shares Out | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
| Weighted Avg Shares Out (Dil) | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before Placing a Bet
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue Estimates
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Relay Therapeutics: Tall Claims, Some Proofs Of Concept, Some Concerns
Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates
Relay Therapeutics: Best-In-Class Potential PIKCA Mutation Inhibitor
Source: https://incomestatements.info
Category: Stock Reports